| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2024 | Singh H, Sahgal P, Kapner K, Corsello SM, Gupta H, Gujrathi R, Li YY, Cherniack AD, El Alam R, Kerfoot J, Andrews E, Lee A, Nambiar C, Hannigan AM, Remland J, et al. RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38345769 DOI: 10.1158/1078-0432.CCR-23-2581 | 0.608 | |||
| 2024 | Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, Chowdhury A, Li YY, Wang X, Spurr L, Pecci F, Di Federico A, Venkatraman D, Barrichello AP, Gandhi M, ... ... Gupta H, et al. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300580. PMID 38207230 DOI: 10.1200/JCO.23.00580 | 0.578 | |||
| 2023 | Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, et al. Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 8321. PMID 38097580 DOI: 10.1038/s41467-023-44124-y | 0.593 | |||
| 2023 | Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 7496. PMID 37980405 DOI: 10.1038/s41467-023-43324-w | 0.637 | |||
| 2023 | Groves A, Ward A, Li YY, Lazo de la Vega L, Nag A, Forrest SJ, Gupta HV, Thorner AR, Meyerson M, Kamihara J, Cherniack AD, Janeway KA. Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatric Blood & Cancer. e30643. PMID 37596911 DOI: 10.1002/pbc.30643 | 0.637 | |||
| 2023 | Singh H, Keller RB, Kapner KS, Dilly J, Raghavan S, Yuan C, Cohen EF, Tolstorukov M, Andrews E, Brais LK, da Silva A, Perez K, Rubinson DA, Surana R, Giannakis M, ... ... Gupta H, et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37463056 DOI: 10.1158/1078-0432.CCR-22-3930 | 0.624 | |||
| 2023 | Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, Spurr LF, Rizvi H, Luo J, Pecci F, Lamberti G, Recondo G, Venkatraman D, Di Federico A, Gandhi MM, et al. Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37247843 DOI: 10.1016/j.jtho.2023.05.019 | 0.617 | |||
| 2023 | Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, et al. Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37097610 DOI: 10.1158/1078-0432.CCR-22-3413 | 0.603 | |||
| 2022 | Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, et al. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. Jco Precision Oncology. 6: e2200390. PMID 36446043 DOI: 10.1200/PO.22.00390 | 0.587 | |||
| 2022 | Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, ... ... Gupta H, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature Medicine. PMID 35739269 DOI: 10.1038/s41591-022-01856-6 | 0.554 | |||
| 2022 | Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, ... ... Gupta H, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Jama Oncology. PMID 35708671 DOI: 10.1001/jamaoncol.2022.1981 | 0.617 | |||
| 2021 | Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, et al. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery. PMID 33926920 DOI: 10.1158/2159-8290.CD-20-1669 | 0.613 | |||
| 2021 | Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33845210 DOI: 10.1016/j.jtho.2021.03.024 | 0.63 | |||
| Show low-probability matches. | |||||